UAE Hemp Law Opens Therapeutic Pathways

(MENAFN- The Arabian Post) Arabian Post Staff -Dubai

Federal reforms regulating industrial hemp are reshaping the treatment landscape for sleep disorders, anxiety and epilepsy across the United Arab Emirates, as clinicians, researchers and regulators map how low-THC cannabis derivatives can be used safely within a tightly controlled system. The changes sit apart from the country's framework on medical cannabis, which governs products with higher tetrahydrocannabinol content and remains subject to strict prescription and import rules.

The hemp law permits the cultivation, processing and use of cannabis varieties containing minimal THC, typically below 0.3 per cent, aligning the UAE with regulatory models adopted in several advanced economies. Officials say the objective is to unlock therapeutic and industrial value without opening pathways to recreational misuse. For patients, the most immediate implications are for cannabidiol-based preparations, which are non-intoxicating and increasingly studied for neurological and psychiatric conditions.

The policy shift creates new clinical options for people whose symptoms have proved resistant to conventional therapies. Insomnia and generalised anxiety disorder affect a growing share of the population, while epilepsy continues to pose treatment challenges for a subset of patients who do not respond adequately to standard anti-seizure medicines. Cannabidiol, or CBD, has drawn attention for its calming effects on the central nervous system and its role in reducing seizure frequency in certain epilepsy syndromes.

Specialists caution that hemp products are not a panacea. Evidence is strongest for specific childhood epilepsies, including Dravet and Lennox-Gastaut syndromes, where purified CBD has been shown to reduce seizure burden when added to existing regimens. Research into anxiety and sleep has produced more mixed findings, though small clinical trials and observational studies suggest benefits for sleep onset and stress modulation at carefully titrated doses.

See also Sony takes control of Peanuts franchise

Professor Barnes, a leading authority on cannabis medicine, notes that the global legal landscape has shifted rapidly. Medical cannabis containing higher THC levels is now legal in 71 countries under varying frameworks, reflecting broader acceptance of cannabinoid-based therapies when appropriately regulated. The UAE's approach, by contrast, draws a bright line between hemp-derived products and medical cannabis, allowing limited therapeutic use while preserving the country's zero-tolerance stance on recreational drugs.

Regulators emphasise that access will be medicalised rather than commercialised. Hemp-derived therapeutics are expected to move through pharmacy channels and clinical oversight, with product quality, labelling and traceability forming core pillars of compliance. Authorities have indicated that cultivation licences will be tightly issued, with genetics, THC thresholds and testing protocols specified to prevent diversion.

Healthcare providers see an opportunity to expand personalised care. Neurologists and psychiatrists report rising patient interest in non-sedating options that can be integrated with existing treatments. For epilepsy specialists, CBD's favourable side-effect profile compared with some traditional anti-epileptic drugs is a significant draw, particularly for long-term management. Sleep physicians, meanwhile, are exploring whether hemp-derived formulations can reduce reliance on hypnotics that carry dependency risks.

Industry participants are preparing cautiously. Pharmaceutical distributors and research institutions are investing in clinical studies tailored to regional populations, recognising that dosage, formulation and delivery methods matter as much as legality. Oils, capsules and oral solutions are expected to dominate, given their dosing precision and lower risk profile compared with inhaled products.

Public health experts underline the need for clear guidance to avoid consumer confusion. Hemp products sold globally range from pharmaceutical-grade medicines to wellness supplements of uneven quality. The UAE framework seeks to close that gap by requiring evidence-based claims and physician involvement, reducing the risk of self-medication or exaggerated expectations.

See also Liveability reshapes Dubai luxury property race

The reforms also intersect with broader innovation goals. By enabling controlled research into cannabinoids, policymakers aim to position the country as a regional hub for life sciences, while maintaining strict ethical standards. Universities and hospitals are already collaborating on protocols to assess safety, efficacy and long-term outcomes in local cohorts.

Notice an issue? Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.

MENAFN05012026000152002308ID1110556018